Registrational Phase 3 study for advanced melanoma immunotherapy delivered with PharmaJet's IM Needle-free System planned for second half 2026.

Expected Revenue Growth. What This Report Will Provide? Target Audience. Based on the technology, the market is divided into Jet-based needle-free injectors, spring-based needle-free injectors, ...

GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet ®, a company who has developed and commercialized an intradermal needle-free platform to more effectively administer drugs and biologics, today announced that ...

The global needle-free injection system market, in terms of value, is projected to reach USD 20.17 Billion by 2021 from USD 9.81 Billion in 2016, at a CAGR of 15.5% during the forecast period. Growth ...

First self-administered, needle-free injection system approved by Health Canada gives access to safe, painless, cost-effective, and more sustainable drug delivery for chronic illnesses Toronto, ...

GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet ®, the maker of innovative, needle-free injection technology, today announced that its Stratis ® Needle-free Injection System will be used to deliver a ...

The PharmaJet Tropis Intradermal (ID) Needle-free System will be used exclusively to deliver vaccine to 1.8 million children in upcoming campaign. To date, 12+ million pediatric injections have been ...

The MarketWatch News Department was not involved in the creation of this content. -- Single-use and reusable needle-free injection devices will be designed for precise self-administration and home use ...